Page 80 - Lipids News Today

Mass spectrometry imaging (MSI) visualizes molecular distributions throughout tissues but is blind to dynamic metabolic processes. Here, MSI with high mass resolution together with multiple stable isotope labeling provided spatial analyses of phosphatidylcholine (PC) metabolism in mouse lungs. Dysregulated surfactant metabolism is central to many respiratory diseases. Metabolism and turnover of therapeutic pulmonary surfactants were imaged from distributions of intact and metabolic products of a...

A new observational study uncovers significant cognitive decline in the years after a myocardial infarction, although not immediately after the event.

A new study suggests a one-time baseline measure of lipoprotein(a) molar concentration might be sufficient to define lifetime risk, rather than repeat testing.

Less than 10% of patients experience statin intolerance, a new meta-analysis shows, meaning that the vast majority of patients can be treated effectively, with very good tolerability, researchers say.

A large, US study found that just 1 in 8 patients with type 2 diabetes received first-line medications for comorbid atherosclerotic cardiovascular disease, heart failure, and diabetic nephropathy.

Patients with both diabetes and atrial fibrillation may derive greater benefits from non-vitamin K oral anticoagulants than from warfarin, a new study has found.

Researchers used cryo-EM to demonstrate that 1PBC, and the drug niclosamide, both inhibitors of TMEM16 proteins, have therapeutic potential and may be used for COVID-19 treatment.

Models using novel biomarkers were the most effective predictors of 10-year risk for atherosclerotic cardiovascular disease in patients with chronic kidney disease, a new study found.

Significant reductions in Lp(a) were sustained out to 150 days in patients without cardiovascular disease in top-line phase 1 results from the APOLLO study, released by Silence Therapeutics.

Three standard equations showed clinically meaningful differences in estimated LDL cholesterol levels in patients with atherosclerotic cardiovascular disease, potentially affecting treatment decisions.